scorecardresearchSun Pharmaceutical Industries Share Price Live NSE, BSE, Today - Sun Pharmaceutical
Mintgenie
Asian Paints2,844.60-16.95 (-0.59%)
Axis Bank1,130.052.70 (0.24%)
Bajaj Finance6,729.85-564.05 (-7.73%)
Bajaj Finserv1,597.10-58.70 (-3.55%)
Bharti Airtel1,325.50-10.45 (-0.78%)
HCL Technologies1,476.80-26.85 (-1.79%)
HDFC Bank1,509.75-0.90 (-0.06%)
Hindustan Unilever2,221.50-9.50 (-0.43%)
ICICI Bank1,107.15-5.90 (-0.53%)
ITC439.952.45 (0.56%)
Indusind Bank1,445.85-50.30 (-3.36%)
Infosys1,430.15-8.25 (-0.57%)
Kotak Mahindra Bank1,608.40-34.60 (-2.11%)
Larsen & Toubro3,602.30-48.35 (-1.32%)
Mahindra & Mahindra2,055.00-40.55 (-1.94%)
Maruti Suzuki India12,687.05-219.05 (-1.70%)
NTPC355.75-2.55 (-0.71%)
Nestle India2,483.80-78.90 (-3.08%)
Power Grid Corporation Of India292.60-0.50 (-0.17%)
Reliance Industries2,903.00-15.40 (-0.53%)
State Bank Of India801.40-11.20 (-1.38%)
Sun Pharmaceutical Industries1,504.25-16.30 (-1.07%)
Tata Consultancy Services3,825.00-26.85 (-0.70%)
Tata Motors999.35-1.45 (-0.14%)
Tata Steel165.85-1.75 (-1.04%)
Tech Mahindra1,277.4587.35 (7.34%)
Titan Company3,584.4011.75 (0.33%)
Ultratech Cement9,735.3551.75 (0.53%)
Wipro464.653.65 (0.79%)

Sun Pharmaceutical Industries

BSE: 524715 | NSE: SUNPHARMA | ISIN: INE044A01036 | SECTOR: Biotechnology & Drugs

₹1,504.25 -16.30 (-1.07%)

26 Apr 2024, 10:14 (IST)

  • Open

    1,529.90

  • High

    1,530.05

  • Low

    1,499.65

  • Prev Close

    1,520.55

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    3,609.20B

  • Volume

    139.36K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    -

  • Ask

    -
View all metrics

Promoter Pledge Holding - 1.12%

Promoter NameNo of SharesPercentage
Kumud Shantilal Shanghvi1,00,0000.00%
Raksha S.Valia2,66,90,0001.11%
Aditya Medisales Limited10,0000.00%

Company Description

  • Biotechnology & Drugs

  • BSE

    524715

  • NSE

    SUNPHARMA

  • ISIN

    INE044A01036

Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company. The Company is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and active pharmaceutical ingredients (APIs). It produces a comprehensive, diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. The Company's vertically integrated network enables it to produce a wide range of pharmaceuticals, including oncology, hormones, peptides, and steroidal drugs. The Company also has a product portfolio in RoW markets, including injectables, hospital products and retail products. It offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, Yonsa, Sezaby and Sprinkle portfolio.

Company Officers

  • C. S. Muralidharan

    Chief Financial Officer

  • Uday Baldota

    Chief Executive Officer - Taro Pharmaceutical Industries Limited

  • S. Damodharan

    Chief Executive Officer - API Business

  • Abhay Gandhi

    Chief Executive Officer - North America

  • Kirti Ganorkar

    Chief Executive Officer - India Business

  • Suresh Rai

    Chief Human Resource Officer, Senior Vice President

  • Dheeraj Sinha

    Executive Vice President, Chief Information Officer

  • Aalok Shanghvi

    Whole-time Director, Executive Vice-President, Emerging Markets, Global generic R&D, Global BD (Generics Segment) & API

  • Jila Breeze

    Executive Vice President, Global Head - Quality

  • Azadar Khan

    Senior Vice-President, Corporate Relations and Corporate Social Responsibility